UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Dynamic Leisure and Entertainment Invesco ETF (PEJ)

Dynamic Leisure and Entertainment Invesco ETF (PEJ)
55.00 x 2 56.05 x 45
Post-market by (Cboe BZX)
54.99 -1.70 (-3.00%) 02/21/25 [NYSE Arca]
55.00 x 2 56.05 x 45
Post-market 54.99 unch (unch) 20:00 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
54.92
Day High
57.06
Open 57.06
Previous Close 56.69 56.69
Volume 58,400 58,400
Avg Vol 53,020 53,020
Stochastic %K 53.14% 53.14%
Weighted Alpha +28.06 +28.06
5-Day Change -1.95 (-3.42%) -1.95 (-3.42%)
52-Week Range 41.20 - 57.93 41.20 - 57.93
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Invesco
  • Assets Under Management 294,471,300
  • Shares Outstanding, K 5,190
  • 60-Month Beta 1.30
  • Price/Earnings ttm 14.98
  • Annual Dividend & Yield 0.21 (0.37%)
  • Most Recent Dividend 0.034 on 09/23/24
  • Management Fee 0.55%
  • INDUSTRY GROUPING:

    ETFs - Consumer Discretionary

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 15.14%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.22 +3.34%
on 01/23/25
Period Open: 53.48
57.93 -5.07%
on 02/18/25
+1.51 (+2.82%)
since 01/21/25
3-Month
51.09 +7.63%
on 01/13/25
Period Open: 53.30
57.93 -5.07%
on 02/18/25
+1.69 (+3.17%)
since 11/21/24
52-Week
41.20 +33.47%
on 08/05/24
Period Open: 42.62
57.93 -5.07%
on 02/18/25
+12.37 (+29.02%)
since 02/21/24

Most Recent Stories

More News
Cinemark Stock Plunges As Q4 EPS Miss Overshadows Record Revenue, Dividend Reinstatement: Retail Shrugs It Off

CEO Sean Gamble attributed the company’s outsized box office proceeds to better-than-expected industry performance.

CNK : 27.45 (-1.22%)
PEJ : 54.99 (-3.00%)
IWM : 217.80 (-2.88%)
Fox Corporation Stock: Analyst Estimates & Ratings

Fox Corporation has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

FOXA : 56.95 (-0.75%)
PEJ : 54.99 (-3.00%)
$SPX : 6,013.13 (-1.71%)
DB : 20.30 (-0.44%)
Are Wall Street Analysts Bullish on Expedia Stock?

Over the past year, Expedia has trailed the broader market, and analysts maintain a cautiously optimistic outlook for the stock’s future performance.

PEJ : 54.99 (-3.00%)
WFC : 77.50 (-1.44%)
$SPX : 6,013.13 (-1.71%)
EXPE : 196.81 (-4.06%)
BYD Gaming Stock Rises In Premarket Following Analyst’s Bullish Recommendation: Retail Sentiment Lags

Jefferies analyst David Katz said the value of Boyd Gaming’s digital presence through FanDuel, which he values at $7 per share, is unappreciated.

PEJ : 54.99 (-3.00%)
GRPM : 110.39 (-1.89%)
BYD : 76.86 (-3.22%)
Feast on a Spread of ETFs This Thanksgiving

With Thanksgiving just a day away, the holiday season is set to begin. Americans will gather with family and friends to give thanks for the blessings in their lives. However, this year could pose some...

AWAY : 22.20 (-2.07%)
COST : 1,035.03 (+0.02%)
EATZ : 28.60 (-3.62%)
PEJ : 54.99 (-3.00%)
RTH : 232.89 (-1.38%)
MILN : 47.26 (-3.25%)
CRUZ : 26.18 (-3.66%)
WMT : 94.78 (-2.50%)
Do Wall Street Analysts Like Fox Corporation Stock?

Fox Corporation has outperformed the broader market over the past year, and Wall Street analysts appear moderately bullish about the stock’s future.

FOXA : 56.95 (-0.75%)
PEJ : 54.99 (-3.00%)
WFC : 77.50 (-1.44%)
$SPX : 6,013.13 (-1.71%)
GS : 625.60 (-2.59%)
What Are Wall Street Analysts' Target Price for Expedia Stock?

Expedia has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

PEJ : 54.99 (-3.00%)
$SPX : 6,013.13 (-1.71%)
EXPE : 196.81 (-4.06%)
UBER : 78.89 (-2.92%)
Are Wall Street Analysts Bullish on Warner Bros. Discovery Stock?

Warner Bros. Discovery has underperformed the broader market this year, but Wall Street analysts are moderately bullish about the stock’s prospects.

PEJ : 54.99 (-3.00%)
$SPX : 6,013.13 (-1.71%)
WBD : 10.78 (-2.36%)
GS : 625.60 (-2.59%)
Fox Corporation Stock Outlook: Is Wall Street Bullish or Bearish?

Fox Corporation has surpassed the broader market this year, yet analysts express cautious optimism regarding the stock’s prospects.

FOXA : 56.95 (-0.75%)
$SPX : 6,013.13 (-1.71%)
PEJ : 54.99 (-3.00%)
JPM : 264.24 (-0.96%)
What Are Wall Street Analysts' Target Price for Warner Bros. Discovery Stock?

Although Warner Bros. Discovery has lagged behind the broader market over the past year, Wall Street analysts hold a cautiously optimistic view of the stock's potential.

WBD : 10.78 (-2.36%)
$SPX : 6,013.13 (-1.71%)
PEJ : 54.99 (-3.00%)
AMZN : 216.58 (-2.83%)
MS : 131.69 (-1.97%)
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds

Citi noted the positive clinical data and the competitive pricing of Attruby at $225,000 per year, below Pfizer’s tafamidis.

BBIO : 36.85 (+0.12%)
VTI : 295.92 (-1.85%)
XBI : 91.70 (-1.10%)
BridgeBio Pharma Announces FDA Approval of Attruby™ to Treat ATTR-CM with Promising Cardiac Outcomes

BridgeBio's Attruby is FDA-approved for ATTR-CM, demonstrating significant cardiovascular benefits and providing lifetime free access for trial participants.Quiver AI SummaryBridgeBio Pharma, Inc. announced...

BBIO : 36.85 (+0.12%)
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BBIO : 36.85 (+0.12%)
Insider Sale: Chief Executive Officer of $BBIO (BBIO) Sells 1,875 Shares

Neil Kumar, the Chief Executive Officer of $BBIO ($BBIO), sold 1,875 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0% of...

BBIO : 36.85 (+0.12%)
Insider Sale: Secretary of $BBIO (BBIO) Sells 4,156 Shares

BRIAN C STEPHENSON, the Secretary of $BBIO ($BBIO), sold 4,156 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.2% of their...

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Positive 18-Month Results for Infigratinib in Achondroplasia from PROPEL 2 Study

Infigratinib shows significant growth improvements in children with achondroplasia, with ongoing trials and FDA breakthrough designations.Quiver AI SummaryBridgeBio Pharma announced positive results from...

BBIO : 36.85 (+0.12%)
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BBIO : 36.85 (+0.12%)
BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma: Q3 Earnings Snapshot

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BBIO : 36.85 (+0.12%)
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds

Citi noted the positive clinical data and the competitive pricing of Attruby at $225,000 per year, below Pfizer’s tafamidis.

BBIO : 36.85 (+0.12%)
VTI : 295.92 (-1.85%)
XBI : 91.70 (-1.10%)
BridgeBio Pharma Announces FDA Approval of Attruby™ to Treat ATTR-CM with Promising Cardiac Outcomes

BridgeBio's Attruby is FDA-approved for ATTR-CM, demonstrating significant cardiovascular benefits and providing lifetime free access for trial participants.Quiver AI SummaryBridgeBio Pharma, Inc. announced...

BBIO : 36.85 (+0.12%)
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BBIO : 36.85 (+0.12%)
Insider Sale: Chief Executive Officer of $BBIO (BBIO) Sells 1,875 Shares

Neil Kumar, the Chief Executive Officer of $BBIO ($BBIO), sold 1,875 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0% of...

BBIO : 36.85 (+0.12%)
Insider Sale: Secretary of $BBIO (BBIO) Sells 4,156 Shares

BRIAN C STEPHENSON, the Secretary of $BBIO ($BBIO), sold 4,156 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.2% of their...

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Positive 18-Month Results for Infigratinib in Achondroplasia from PROPEL 2 Study

Infigratinib shows significant growth improvements in children with achondroplasia, with ongoing trials and FDA breakthrough designations.Quiver AI SummaryBridgeBio Pharma announced positive results from...

BBIO : 36.85 (+0.12%)
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BBIO : 36.85 (+0.12%)
BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma: Q3 Earnings Snapshot

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BBIO : 36.85 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The Invesco Dynamic Leisure and Entertainment ETF is based on the Dynamic Leisure and Entertainment Intellidex Index. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly...

See More

Key Turning Points

3rd Resistance Point 58.53
2nd Resistance Point 57.80
1st Resistance Point 56.39
Last Price 54.99
1st Support Level 54.25
2nd Support Level 53.52
3rd Support Level 52.11

See More

52-Week High 57.93
Last Price 54.99
Fibonacci 61.8% 51.54
Fibonacci 50% 49.56
Fibonacci 38.2% 47.59
52-Week Low 41.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements